Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4535-4543

  Yan, Yang ^a   Li, Songyan ^a   Jia, Tingting ^a   Du, Xiaohui ^a   Xu, Yingxin ^a   Zhao, Yunshan ^a   Li, Li ^a   Liang, Kai ^a   Liang, Wentao ^a   Sun, Huiwei ^a   Li, Rong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CTL cells; IL 15; Oncolytic adenovirus

Indexed keywords

INTERLEUKIN 15; ONCOLYTIC ADENOVIRUS; TRANSCRIPTION FACTOR E2F1; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CELL THERAPY; CELLULAR IMMUNITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE CONSTRUCT; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL DESTRUCTION; VIRUS REPLICATION; ADAPTIVE IMMUNITY; ADENOVIRIDAE; COLONIC NEOPLASMS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; ONCOLYTIC VIROTHERAPY; TUMOR CELL LINE; VIROLOGY;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938961006     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3098-7     Document Type: Article

References (44)

1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–70.
2. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008;8:1581–8.
3. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets. 2007;7:133–9.
4. Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther. 2013;20:70–6.
5. Choi JW, Lee JS, Kim SW, Yun CO. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev. 2012;64:720–9.
6. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 2011;22:99–108.
7. Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I. Interleukin-15 in gene therapy of cancer. Curr Gene Ther. 2013;13:15–30.
8. Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol. 2002;169:4928–35.
9. Davies E, Reid S, Medina MF, Lichty B, Ashkar AA. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. J Leukoc Biol. 2010;88:529–36.
10. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771–80.
11. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669–76.
12. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A. 2000;97:11445–50.
13. Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, Yoshikai Y. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer J Int Cancer. 2002;99:573–8.
14. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol. 2007;37:1678–90.
15. King JW, Thomas S, Corsi F, Gao L, Dina R, Gillmore R, et al. IL15 can reverse the unresponsiveness of Wilms’ tumor antigen-specific CTL in patients with prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:1145–54.
16. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 2012;19:238–46.
17. Liu J, Wennier S, Reinhard M, Roy E, MacNeill A, McFadden G. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol. 2009;83:5933–8.
18. Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA, et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res. 2010;70:1072–81.
19. Nguyen TL, Wilson MG, Hiscott J. Oncolytic viruses and histone deacetylase inhibitors—a multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev. 2010;21:153–9.
20. Fujiwara T, Kagawa S, Tazawa H. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer. Curr Pharm Biotechnol. 2012;13:1809–16.
21. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther. 2009;9:422–7.
22. Darcy PK, Neeson P, Yong CS, Kershaw MH. Manipulating immune cells for adoptive immunotherapy of cancer. Curr Opin Immunol. 2014;27C:46–52.
23. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.
24. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat Rev Clin Oncol. 2011;8:577–85.
25. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
26. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009;49:124–32.
27. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99:16168–73.
28. June CH. Adoptive T, cell therapy for cancer in the clinic. J Clin Invest. 2007;117:1466–76.
29. Yang Z, Zhang Q, Xu K, Shan J, Shen J, Liu L, et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS ONE. 2012;7:e44802.
30. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, Yun CO. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther: J Am Soc Gene Ther. 2011;19:1558–68.
31. Yan Y, Xu Y, Zhao Y, Li L, Sun P, Liu H, et al. Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model. Tumour Biol: J Int Soc OncoDev Biol Med. 2014;35:1113–22.
32. Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin. 2009;30:467–77.
33. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517–25.
34. Du X, Jin R, Ning N, Li L, Wang Q, Liang W, et al. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep. 2012;28:1743–9.
35. Sun P, Xu Y, Du X, Ning N, Sun H, Liang W, et al. An engineered three-dimensional gastric tumor culture model for evaluating the antitumor activity of immune cells in vitro. Oncol lett. 2013;5:489–94.
36. Du X, Wang X, Ning N, Xia S, Liu J, Liang W, et al. Dynamic tracing of immune cells in an orthotopic gastric carcinoma mouse model using near-infrared fluorescence live imaging. Exp Ther Med. 2012;4:221–5.
37. Mao CY, Hua HJ, Chen P, Yu DC, Cao J, Teng LS. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma. Hepato-Biliary-Pancreat Dis Int: HBPD INT. 2009;8:282–7.
38. Zhang J, Ramesh N, Chen Y, Li Y, Dilley J, Working P, et al. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res. 2002;62:3743–50.
39. Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, et al. Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer. J Gastroenterol. 2005;40:31–42.
40. Gurlevik E, Woller N, Struver N, Schache P, Kloos A, Manns MP, et al. Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity. Mol Ther: J Am Soc Gene Ther. 2010;18:1972–82.
41. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor—armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2006;12:305–13.
42. Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 2007;14:918–26.
43. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther. 2009;16:473–88.
44. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, Rezaei N, et al. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol. 2004;203:744–53.